Baroda BNP Paribas Health And Wellness Fund Regular Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 09-06-2025
AUM:
₹ 553.17 Cr
Expense Ratio
2.74%
Benchmark
BSE Healthcare TRI
ISIN
INF251K01UY7
Minimum Investment
1000.0
Minimum Topup
1000.0
Minimum SIP Amount
500
Fund Manager
Mr. Sanjay Chawla, Mr. Rohan Korde
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Baroda BNP Paribas Health And Wellness Fund Regular Growth | 4.97 | - | - |
| Benchmark | - | - | - |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
10.604
Last change
0.16 (1.5136%)
Fund Size (AUM)
₹ 553.17 Cr
Performance
5.53% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund Manager
Mr. Sanjay Chawla, Mr. Rohan Korde
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.09 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 5.83 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 5.76 |
| ABBOTT INDIA LIMITED EQ | 5.43 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 5.27 |
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 5.18 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 4.66 |
| JB Chemicals & Pharmaceuticals Limited | 4.38 |
| FORTIS HEALTHCARE LIMITED. EQ | 4.27 |
| ASTRAZENECA PHARMA INDIA LIMITED EQ NEW FV RS.2/- | 4.12 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 86.95 |
| Financial Services | 7.27 |
| Consumer Services | 1.65 |
| Information Technology | 1.54 |